Nabi Biopharmaceuticals Continues Clinical Development of StaphVax (NABI)

Last November, Nabi Biopharmaceuticals (ticker: NABI) announced that the confirmatory Phase 3 study of StaphVax failed to meet its primary endpoint. Because the results were contrary to what the company predicted would occur, they formed an outside advisory panel to determine what caused the “unexpected results.